Interventional study with open label/non-randomised methodology (Yellow)
ZyCoV-D is a DNA vaccine candidate, which comprises a plasmid DNA carrying spike-S gene of
SARS-CoV-2 virus along with gene coding for signal peptide. The spike(S) region includes the receptor-binding domain (RBD), which binds to the human angiotensin converting Enzyme (ACE)-2 receptor and mediates the entry of virus inside the cell. In this article the authors conducted a single-center, open-label, non-randomized, Phase 1 trial in India between July 2020 and October 2020. Healthy adults aged between 18 and 55 years were sequentially enrolled and allocated to one of four treatment arms in a dose escalation manner. Three doses of vaccine were administered 28 days apart and each subject was followed up for 28 days post third dose to evaluate safety and immunogenicity.
Out of 126 individuals screened for eligibility. Forty-eight subjects (mean age 34.9 years) were
enrolled and vaccinated in the Phase 1 study Overall, 12/48 (25%) subjects reported at least one AE (i.e. combined solicited and unsolicited) during the study. There were no deaths or serious adverse events reported in Phase 1 of the study. The proportion of subjects who seroconverted based on IgG titers on day 84 was 4/11 (36.36%), 4/12 (33.33%), 10/10 (100.00%) and 8/10 (80.00%) in the treatment Arm 1 (1 mg: Needle), Arm 2 (1 mg: NFIS), Arm 3 (2 mg: Needle) and Arm 4 (2 mg: NFIS), respectively. The authors concluded that ZyCoV-D vaccine is found to be safe, well-tolerated and immunogenic in the Phase 1 trial.
Momin, Taufik et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine, Volume 38, 101020 DOI: doi.org/10.1016/j.eclinm.2021.101020
